What is synthetic lethality? The principle that is rekindling cancer drug research

A decade ago, the concept of synthetic lethality was largely an academic curiosity in the genetics literature. Today, according to STAT News, the concept has become the scientific principle behind a new wave of mergers and acquisitions among biotech investors and big pharma. Understanding the idea is key to seeing why it is drawing so much attention.

The principle can be summarised cleanly: within a cell there are two genes; when either gene is deleted on its own, the cell survives, but when both are deleted, the cell dies. This "synthetic" — meaning artificially created — lethality opens a way to turn a gene that cancer cells have already lost into an advantage. Healthy cells retain both genes, while cancer cells die selectively when the second target is inhibited.

The clearest clinical translation of the concept came with PARP inhibitors. In breast and ovarian cancer cells carrying a BRCA1 or BRCA2 mutation, blocking the PARP enzyme collapses the cell's DNA repair machinery and produces selective cell death. The approach gave rise to drugs such as AstraZeneca's Lynparza and GSK's Zejula and built multi-billion-dollar markets.

The STAT News report emphasises that second-generation synthetic lethality targets are now at the centre of investor attention. Enzymes such as WRN, USP1, PRMT5 and POLQ are at the top of that list. Each has the potential to work selectively in a different cancer subgroup — for example in microsatellite-unstable tumours or in MTAP-deleted cancers.

Why a wave of M&A? Because the synthetic lethality field is in the hands of small biotech start-ups with deep scientific expertise. Big drugmakers like Pfizer, Merck, BMS and Roche can add programmes to their portfolios faster by acquiring those start-ups than by spending years building them internally. Lynparza's success reinforces the expectation that "the market will grow once clinical proof is in."

For investors, there are three main risks. First, the theoretical prediction of synthetic lethality targets does not always match laboratory reality: many targets identified by computational methods could not be validated in CRISPR screens. Second, resistant clones can emerge quickly. Third, drug-and-diagnostic pairs require coordinated approval on the market: as with PARP inhibitors, the genetic test that selects patients is what conditions reimbursement.

STAT also notes that the principle is not confined to cancer. Synthetic lethality could be a basis for targeted killing reactions in neurological disease and infection. For now, however, the most mature clinical programmes are in oncology; the next five years look unlikely to be quiet either in oncological readouts or in M&A financing.

Three clinical programmes Vesper readers should track are these. First, Tango Therapeutics' USP1 inhibitor, which may help patients with BRCA-mutant tumours who develop resistance to Lynparza. Second, IDEAYA Biosciences' PRMT5 inhibitor targeting MTAP deletion — the first selective molecule for an important subgroup of lung cancer. Third, Repare Therapeutics' POLQ inhibitor, positioned as a double-targeting strategy in tumours with homologous recombination deficiency.

On the financial side, analysts show that annual M&A volume around synthetic lethality has roughly tripled since 2023. Behind that lies a scarcity of clinically advanced assets inside small start-up portfolios and pressure on big drugmakers to protect their patent income. One source cited by STAT News says, "a new partnership in the field is announced every month."

The key message: synthetic lethality is not a single drug name or a treatment promise; it is a design principle that could reshape how clinical oncology is built. For oncologists in Türkiye, the practical implication is that wider availability of BRCA testing will open additional treatment options of this class for a broader patient population in the future. Synthetic lethality is emerging as a concrete extension of the oncological mindset that reads cancer's molecular map and tailors therapy to it.